Trials / Completed
CompletedNCT03943576
Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells (GXCPC1) for Knee Osteoarthritis
Adipose-Derived Stem Cells (ADSCs) Injections for Knee Osteoarthritis
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Gwo Xi Stem Cell Applied Technology Co., Ltd. · Industry
- Sex
- All
- Age
- 40 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The aim of the investigators study was to investigate the safety and efficacy of allogeneic ADSCs for the clinical treatment of knee osteoarthritis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GXCPC1 | The dose regimen is one single intra-articular injection of GXCPC1 containing 6.7×10\^6 or 4×10\^7 ADSCs in 3 mL saline. (allogeneic injection) |
| DEVICE | HA | Hya Joint Plus synovial fluid supplement 3mL |
Timeline
- Start date
- 2019-12-01
- Primary completion
- 2022-04-27
- Completion
- 2023-03-22
- First posted
- 2019-05-09
- Last updated
- 2023-06-06
Locations
1 site across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT03943576. Inclusion in this directory is not an endorsement.